Drug intelligence / Profile preview

OC201 + OC202e

Development stage: Preclinical
Lead developer: Oncocross
Modality: Small Molecules
Administration: Oral

Overview

OC201 + OC202e is an investigational drug combination being developed by Oncocross Australia, a subsidiary of the South Korean AI-driven biotech Oncocross. The combination is specifically designed for the inhibition of cancer metastasis. It was identified using the proprietary RAPTOR AI™ platform, which analyzes RNA expression data to find optimal drug pairings (Anti-symmetrical Pairing) for specific therapeutic effects. As of early 2024, the program has reached the Investigational New Drug (IND) stage of development. While the specific active pharmaceutical ingredients and their molecular targets remain undisclosed, the development approach suggests a focus on modulating transcriptomic signatures associated with metastatic progression.

Targets

AKT (RAC-alpha serine/threonine-protein kinase)

Beyond the preview

Go deeper on OC201 + OC202e.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OC201 + OC202e.

Explore the full profile